Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Zone-En Lee

Gastroenterology Largo, MD Medical Doctor

NPI 1437316593 CMS profile 802881

1221 Mercantile Ln, Largo, MD 20774

Open in the dashboard

General payments

$6,225

329 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Zone-En Lee of Largo, MD is reported in the CMS Open Payments database as having received $6,225 across 329 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,306 67
2024 General $2,033 96
2023 General $2,035 123
2022 General $594 37
2021 General $73 5
2019 General $183 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Zone-En Lee
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Zone-En Lee were reported at $1,306. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Zone-En Lee Gastroenterology median Middle half National median
2019 $183 $417 $126–$1,100 $163
2020 $0 $224 $74–$624 $114
2021 $73 $352 $106–$1,054 $132
2022 $594 $448 $129–$1,270 $149
2023 $2,035 $533 $150–$1,390 $160
2024 $2,033 $605 $160–$1,606 $164
2025 $1,306 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,129 64 payments
  2. Celgene Corporation $1,037 74 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $796 44 payments
  4. Janssen Biotech, Inc. $647 39 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $430 20 payments
  6. Genzyme Corporation $363 18 payments
  7. E.R. Squibb & Sons, L.L.C. $296 3 payments
  8. Lilly USA, LLC $283 13 payments
  9. Regeneron Healthcare Solutions, Inc. $280 14 payments
  10. Phathom Pharmaceuticals, Inc. $240 12 payments
  11. Other $725 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,225 329 payments
Products named General payments · program years 2019–2025
  1. ZEPOSIA $1,213 76 payments
  2. RINVOQ $937 52 payments
  3. ENTYVIO $796 44 payments
  4. STELARA $486 31 payments
  5. SKYRIZI Immunology $419 25 payments
  6. SKYRIZI Immunology $378 20 payments
  7. DUPIXENT $363 18 payments
  8. XIFAXAN $358 16 payments
  9. TREMFYA $280 9 payments
  10. OMVOH $260 12 payments
  11. Other $1,741 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

318

Median for Internal Medicine: 777

Drug cost

$87,070

Median for Internal Medicine: $73,373

Branded share of claims

48.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vemlidy Tenofovir Alafenamide Brand 37 $51,696
Linzess Linaclotide Brand 15 $11,558
Voquezna Vonoprazan Fumarate Brand 11 $9,843
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 55 $9,490
Omeprazole Generic 86 $1,433
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 14 $895
Rabeprazole Sodium Generic 13 $556
Dicyclomine Hcl Generic 19 $536
Pantoprazole Sodium Generic 28 $512
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 23 $324

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$128,279

Of which drugs: $71,375

Medicare patients

276

Average age 73

Services billed

5,248

199 women, 77 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 46%
Diabetes 30%
Osteoporosis 26%
Ischemic heart disease 21%
Depression 18%
Cancer 14%
Chronic kidney disease 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $397
$397 — —
ZEPOSIA
  • Celgene Corporation $218
  • E.R. Squibb & Sons, L.L.C. $97
$315 — —
TREMFYA
  • Janssen Scientific Affairs, LLC $119
  • Janssen Biotech, Inc. $71
$189 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $185
$185 11 —
RINVOQ
  • AbbVie, Inc. $173
$173 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

329 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record